We have read the interesting paper by Costa and Saxenaentitled ‘‘Surgical chylothorax in neonates: management andoutcomes”, recently published in the World Journal of Pediatrics[ 1 ]. There are few points of the ar...We have read the interesting paper by Costa and Saxenaentitled ‘‘Surgical chylothorax in neonates: management andoutcomes”, recently published in the World Journal of Pediatrics[ 1 ]. There are few points of the article that we wouldlike to discuss. We recently published a systematic reviewfocusing on the use of octreotide for congenital and acquiredchylothorax in newborns [ 2 ]. Our review concluded thatoctreotide was safe and eff ective in the treatment of chylothoraxin newborns, especially for the congenital forms, andthat octreotide therapy should be considered as an adjunctivetreatment in term and preterm neonates aff ected by congenitaland acquired chylothorax.展开更多
To the editor:We read with great interest the excellent article by Guo et al1 describing causes and manifestations of chylothorax in children in China.There are few points of the article we would like to discuss.The a...To the editor:We read with great interest the excellent article by Guo et al1 describing causes and manifestations of chylothorax in children in China.There are few points of the article we would like to discuss.The authors affirmed that finding seven cases affected by congenital lymphatic malformations was surprisingly.It is not clear if seven cases were considered as a low or high incidence rate.Usually,congenital chylothorax of the newborn may be linked to congenital thoracic duct defects,isolated or associated with generalized lymphatic vessel dysplasia,which is the more likely cause;more rarely,congenital chylothorax is the result of trauma at birth,malignancies,thrombosis of the superior vena cava or subclavian vein causing high central venous pressure.展开更多
文摘We have read the interesting paper by Costa and Saxenaentitled ‘‘Surgical chylothorax in neonates: management andoutcomes”, recently published in the World Journal of Pediatrics[ 1 ]. There are few points of the article that we wouldlike to discuss. We recently published a systematic reviewfocusing on the use of octreotide for congenital and acquiredchylothorax in newborns [ 2 ]. Our review concluded thatoctreotide was safe and eff ective in the treatment of chylothoraxin newborns, especially for the congenital forms, andthat octreotide therapy should be considered as an adjunctivetreatment in term and preterm neonates aff ected by congenitaland acquired chylothorax.
文摘To the editor:We read with great interest the excellent article by Guo et al1 describing causes and manifestations of chylothorax in children in China.There are few points of the article we would like to discuss.The authors affirmed that finding seven cases affected by congenital lymphatic malformations was surprisingly.It is not clear if seven cases were considered as a low or high incidence rate.Usually,congenital chylothorax of the newborn may be linked to congenital thoracic duct defects,isolated or associated with generalized lymphatic vessel dysplasia,which is the more likely cause;more rarely,congenital chylothorax is the result of trauma at birth,malignancies,thrombosis of the superior vena cava or subclavian vein causing high central venous pressure.
